Solitary sclerosis

  title={Solitary sclerosis},
  author={William F. Schmalstieg and B. Mark Keegan and Brian G. Weinshenker},
  pages={540 - 544}
Objective: To present a case series of patients with progressive myelopathy in the setting of a solitary demyelinating lesion. Methods: We describe 7 patients evaluated over a 6-year period. All had progressive motor impairment attributable to an MRI lesion compatible with a demyelinating plaque in the brainstem or upper cervical spinal cord. At the time of evaluation, none met the International Panel imaging criteria for dissemination in space, and none described clinical symptoms consistent… 

Tables from this paper

Long-term outcome in multiple sclerosis patients treated with fingolimod.

Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions

The “critical” demyelinating lesion rather than total brain MRI lesion burden is the major contributor to motor-progression onset in these cohorts with highly restricted versus unlimited magnetic resonance imaging (MRI) lesionurden.

Cerebral hemodynamics in patients with multiple sclerosis.

Critical spinal cord lesions associate with secondary progressive motor impairment in long-standing MS: A population-based case-control study

Investigating whether similar spinal cord lesions are more frequent in long-standing MS patients with secondary progressive motor impairment versus those maintaining a relapsing-remitting course found only the presence of potential critical lesions independently associated with motor progression was linked to motor progression.

Unilateral motor progression in MS

In patients with MS with unilateral motor progression, the motor deficit may be attributable to a single critical corticospinal tract lesion.

Phases and Phenotypes of Multiple Sclerosis.

It is suggested that interventions to prevent progressive MS, when they become available for clinical practice, may need to be considered as early as when the asymptomatic radiologically isolated syndrome is detected.



Interferon beta-1b in secondary progressive MS: Results from a 3-year controlled study

Although no treatment benefit was seen on the time to confirmed progression of disability, relapse- and MRI- related outcomes showed significant benefit with both dosing regimens tested, a result consistent with the outcomes of earlier clinical trials.

Randomized controlled trial of interferon-beta-1a in secondary progressive MS

Interferon-β-1a used in SPMS showed significant effects on all MRI measures, particularly in patients with relapses in the 2 years before the study, and Neutralizing antibody development was associated with reduction in treatment effect.

Randomized controlled trial of interferon- beta-1a in secondary progressive MS

  • Medicine, Psychology
  • 2001
Treatment with interferon beta-1a did not significantly affect disability progression in this cohort, although significant treatment benefit was observed on exacerbation-related outcomes.

Interferon beta-1b in secondary progressive MS

Although no treatment benefit was seen on the time to confirmed progression of disability, relapse- and MRI-related outcomes showed significant benefit with both dosing regimens tested, a result consistent with the outcomes of earlier clinical trials.

Some clinical and pathologic observations on chronic myelopathy: a variant of multiple sclerosis.

Four patients with progressive demyelinating myelopathy with symptoms spanning six to 25 years are described; in all cases but one, oligoclonal bands were detected on cerebrospinal fluid (CSF) electrophoresis.

A secondary progressive clinical course is uncommon in neuromyelitis optica

The disparate natural histories of MS and NMO suggest dissociation between relapses and clinical progression in CNS demyelinating diseases.

Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial

To determine whether glatiramer acetate slows accumulation of disability in primary progressive multiple sclerosis, a new drug is developed that acts as a ‘spatially aggregating agent’ to reduce the risk of disease progression.

Idiopathic inflammatory-demyelinating diseases of the central nervous system

Precise classification of these disorders may have relevant prognostic and treatment implications, and might be helpful in distinguishing them from tumoral or infectious lesions, avoiding unnecessary aggressive diagnostic or therapeutic procedures.

The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease.

It is demonstrated that the progressive course is independent of relapses either preceding the onset of relapse-free progression or subsequent to it, and among SAP patients, the degree of recovery from the single defining exacerbation had no significant effect on outcome.

The contribution of demyelination to axonal loss in multiple sclerosis.

The traditional notion that multiple sclerosis is a primary demyelinating disease has led to a plaque-centred view of both aetiology and the pathogenesis of disease progression, but the possibility that demYelination is not the primary determinant of spinal cord axonal loss warrants consideration.